Eastern Equine Encephalitis - Pipeline Review, H1 2020

June 2020 | 41 pages | ID: E44CA6931709EN
Global Markets Direct

Abstracts

Eastern Equine Encephalitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.
Eastern equine encephalitis is a disease that is spread to humans by infected mosquitoes. Eastern equine encephalitis is caused by the Eastern equine encephalitis virus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.
Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Eastern Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Eastern Equine Encephalitis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Eastern Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Eastern Equine Encephalitis - Overview
Eastern Equine Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Eastern Equine Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Eastern Equine Encephalitis - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
Profectus BioSciences Inc
Ridgeback Biotherapeutics LP
Eastern Equine Encephalitis - Drug Profiles
EIDD-2801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
encephalitis (trivalent,virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Eastern Equine Encephalitis and Venezuelan Equine Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSI-GSD-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eastern Equine Encephalitis - Dormant Projects
Eastern Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Apr 18, 2019: UofL researcher developing drug to treat emerging encephalitis viruses
Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Eastern Equine Encephalitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Eastern Equine Encephalitis - Pipeline by Bavarian Nordic A/S, H1 2020
Eastern Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H1 2020
Eastern Equine Encephalitis - Pipeline by Ridgeback Biotherapeutics LP, H1 2020
Eastern Equine Encephalitis - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Eastern Equine Encephalitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Bavarian Nordic A/S
Profectus BioSciences Inc
Ridgeback Biotherapeutics LP